Ga-dotatoc F-FDG Radiolabelled PSMA PET/CT in Renal Cancer Patients

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2019 Oct 3

PMID 31576357

Citations 3

Authors

Laura Evangelista

Fabio Zattoni

Pierpaolo Alongi

Affiliations

Soon will be listed here.

Citing Articles

The role of [ Ga]Ga-FAPI-04 PET/CT in renal cell carcinoma: a preliminary study.

Civan C, Kuyumcu S, Simsek D, Sanli O, Isik E, Ozkan Z Eur J Nucl Med Mol Imaging. 2023; 51(3):852-861.

PMID: 37803246 DOI: 10.1007/s00259-023-06461-4.

Recent advances in imaging techniques of renal masses.

Aggarwal A, Das C, Sharma S World J Radiol. 2022; 14(6):137-150.

PMID: 35978979 PMC: 9258310. DOI: 10.4329/wjr.v14.i6.137.

MicroRNA-384 inhibits nasopharyngeal carcinoma growth and metastasis via binding to Smad5 and suppressing the Wnt/β-catenin axis.

Zeng X, Liao H, Wang F Cytotechnology. 2021; 73(2):203-215.

PMID: 33911345 PMC: 8035371. DOI: 10.1007/s10616-021-00458-3.

References

Baccala A, Sercia L, Li J, Heston W, Zhou M . Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007; 70(2):385-90. DOI: 10.1016/j.urology.2007.03.025. View

Kakizoe M, Yao M, Tateishi U, Minamimoto R, Ueno D, Namura K . The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. BMC Cancer. 2014; 14:390. PMC: 4067124. DOI: 10.1186/1471-2407-14-390. View

Chen J, Appelbaum D, Kocherginsky M, Cowey C, Rathmell W, Mcdermott D . FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013; 2(4):545-52. PMC: 3799289. DOI: 10.1002/cam4.102. View

Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R . New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol. 2016; 70(1):161-175. DOI: 10.1016/j.eururo.2016.01.029. View

Janzen N, Kim H, Figlin R, Belldegrun A . Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003; 30(4):843-52. DOI: 10.1016/s0094-0143(03)00056-9. View

Choudhary S, Rajesh A, Mayer N, Mulcahy K, Haroon A . Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. Clin Radiol. 2009; 64(5):517-22. DOI: 10.1016/j.crad.2008.12.011. View

Giannarini G, Petralia G, Thoeny H . Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol. 2011; 61(2):326-40. DOI: 10.1016/j.eururo.2011.09.019. View

Ferda J, Ferdova E, Hora M, Hes O, Finek J, Topolcan O . 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Anticancer Res. 2013; 33(6):2665-72. View

Smaldone M, Uzzo R . Balancing process and risk: standardizing posttreatment surveillance for renal cell carcinoma. J Urol. 2013; 190(2):417-8. DOI: 10.1016/j.juro.2013.05.033. View

10.

Ravina M, Hess S, Chauhan M, Jacob M, Alavi A . Tumor thrombus: ancillary findings on FDG PET/CT in an oncologic population. Clin Nucl Med. 2014; 39(9):767-71. DOI: 10.1097/RLU.0000000000000451. View

11.

Chang S, Reuter V, Heston W, Gaudin P . Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology. 2001; 57(4):801-5. DOI: 10.1016/s0090-4295(00)01094-3. View

12.

Kang D, White Jr R, Zuger J, Sasser H, Teigland C . Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004; 171(5):1806-9. DOI: 10.1097/01.ju.0000120241.50061.e4. View

13.

Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K . The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol. 2009; 79(1):29-35. DOI: 10.1016/j.ejrad.2009.11.019. View

14.

Caldarella C, Muoio B, Isgro M, Porfiri E, Treglia G, Giovanella L . The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiol Oncol. 2014; 48(3):219-27. PMC: 4110077. DOI: 10.2478/raon-2013-0067. View

15.

Czarnecka A, Kornakiewicz A, Kukwa W, Szczylik C . Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. Future Oncol. 2014; 10(6):1095-111. DOI: 10.2217/fon.13.258. View

16.

Sharma P, Kumar R, Jeph S, Karunanithi S, Naswa N, Gupta A . 18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus?. Nucl Med Commun. 2011; 32(9):782-8. DOI: 10.1097/MNM.0b013e32834774c8. View

17.

Pedrosa I, Sun M, Spencer M, Genega E, Olumi A, DeWolf W . MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics. 2008; 28(4):985-1003. DOI: 10.1148/rg.284065018. View

18.

Nakamoto Y, Ishimori T, Shimizu Y, Sano K, Togashi K . Clinical utility of Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019; 46(7):1524-1530. DOI: 10.1007/s00259-019-04298-4. View

19.

Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman M . Utility of Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol. 2017; 61(3):372-378. DOI: 10.1111/1754-9485.12590. View

20.

Pillai M, Nanabala R, Joy A, Sasikumar A, Knapp F . Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol. 2016; 43(11):692-720. DOI: 10.1016/j.nucmedbio.2016.08.006. View